PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...
It starts with a portfolio of defensive, low-volatility stocks, aiming to reduce downside risk. But it doesn't write covered calls directly on these stocks. Instead, it allocates about 15% of its ...
(Apologies for the one-week delay — I initially posted this to the wrong feed -b) Discussed in this episode: Influenza levels are rising quickly This year’s flu vaccine appears to be reducing the risk ...
What are PTC Inc Insiders Doing? At PTC Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 675.00 shares worth $106.14K, meanwhile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results